
TRVI Stock Forecast & Price Target
TRVI Analyst Ratings
Bulls say
Trevi Therapeutics is likely to see success and positive clinical results in its upcoming late-stage trials for Haduvio, which could lead to its development and eventual commercialization for the treatment of IPF cough, RCC, and non-IPF ILD. The company has demonstrated strong clinical results for Haduvio in multiple cough indications and has a large potential market opportunity. Investor attention may also be drawn to the upcoming readout of GSK's camlipixant trial, which could have a beneficial impact on TRVI. The company has a strong cash position and is well-positioned to continue advancing Haduvio towards commercialization, with potential partnerships in the future to address broader market opportunities.
Bears say
Trevi Therapeutics is facing significant financing and regulatory risks as they continue to incur high operating expenses for the clinical development of Haduvio in multiple indications, including IPF cough and refractory chronic cough. Despite a trend toward reduced cough frequency, most patients have reported unsuccessful attempts at treating their cough, potentially hindering the success of Haduvio. Additionally, the company will need additional capital to support the development and potential commercialization of Haduvio, adding to the financial risk of investing in this stock.
This aggregate rating is based on analysts' research of Trevi Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TRVI Analyst Forecast & Price Prediction
Start investing in TRVI
Order type
Buy in
Order amount
Est. shares
0 shares